Intellectual Property and Technology Litigation

At Moarbes, LLP, we believe intellectual property litigation should only be used as the last resort, after it is clear no business solution is possible.  In that situation, only the Courts can provide what the market cannot: a fair and reasonable resolution. 

An example of some of the matters the head of our IP practice, Mr. Geoffrey Mason, has litigated with this philosophy are as follows.

Eli Lilly v. Wockhardt et al. Defended Wockhardt against two Lilly patents covering duloxetine (Cymbalta®), a $5 billion drug in the United States alone. Developed defenses that convinced Wockhardt to litigate solo against Eli Lilly after all remaining defendants ceased to actively litigate.
Johnson and Johnson v. Andrx Asserted two patents against defendant seeking to make generic Concerta®. Convinced opposing counsel to drop sole enforceability defense immediately following successful cross-examination of key expert relating to defense; for most of the case, acted as sole attorney working with the majority of J&J's technical experts.
Aventis v. Teva et al. Asserted patent against defendants seeking to make generic Lovenox®. Drafted motion for trial date shift that resulted in saving Aventis as much as $200 million; headed all discovery efforts at issue in said motion.
Igen (later Bioveris) v. Roche et al. Asserted five patents against Roche relating to its use of ECL. Acted as most senior full time attorney; case settled successfully for $1.4 billion.
GSK v. Teva et al. Asserted seven patents against defendants seeking to make generic Augmentin®. Acted as primary drafter of GSK's Trial Findings of Fact & Conclusions of Law.
Connaught v. GSK Defended GSK against patent infringement claim by Connaught relating to GSK's DPT vaccine. As co-attorney, prevailed in professional mock jury trial against leading patent attorney Donald Dunner.